How much does idarucizumab cost (typical list price) in the US?
Idarucizumab (Praxbind) is priced and reimbursed differently by country and payer, and the exact “price” depends on whether you’re looking for the US list price, a hospital contract price, or the amount actually paid after insurance.
If you tell me the country (and whether you want US list price vs. typical reimbursement), I can narrow to the most relevant figure.
What does idarucizumab cost per treatment?
Idarucizumab is used as an emergency reversal for dabigatran anticoagulation, and dosing is typically fixed per course rather than adjusted by weight for the approved indication. The total cost you’ll see is therefore usually calculated from the drug’s per-dose vial/pack price multiplied by the number of vials needed for the prescribed regimen.
Why do prices vary so much for Praxbind?
The same product price can look very different across sources because of:
- payer discounts and hospital contract pricing,
- channel (wholesale acquisition cost vs. net price vs. cash price),
- reimbursement practices (especially for inpatient emergency use),
- country-specific markups and procurement.
Are there cheaper alternatives or biosimilar-like options?
Idarucizumab is a specific antidote product for dabigatran reversal. The availability of lower-cost alternatives depends on local market approvals, procurement, and whether any competing antidote products are approved where you live. If you share your location, I can check the relevant competitive landscape.
What’s the fastest way to get an accurate number for your situation?
To quote the most accurate “idarucizumab price,” you usually need:
- country (and state/province if relevant),
- whether you want list price, estimate of net cost, or out-of-pocket cost,
- whether it’s for a hospital/institution purchase or a patient cash price.
Reply with your country and whether you want US list price, hospital/net price, or patient out-of-pocket, and I’ll narrow the answer.